Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis

OBJECTIVE: Cases of inflammatory bowel disease (IBD) during treatment with interleukin (IL)-17 antagonists have been reported from trials in psoriasis, psoriatic arthritis, and ankylosing spondylitis. The aim of this study was to assess the overall risk for development of IBD due to IL-17 inhibition...

Descripción completa

Detalles Bibliográficos
Autores principales: Burisch, Johan, Eigner, Wolfgang, Schreiber, Stefan, Aletaha, Daniel, Weninger, Wolfgang, Trauner, Michael, Reinisch, Walter, Narula, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252630/
https://www.ncbi.nlm.nih.gov/pubmed/32459816
http://dx.doi.org/10.1371/journal.pone.0233781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252630/
https://www.ncbi.nlm.nih.gov/pubmed/32459816
http://dx.doi.org/10.1371/journal.pone.0233781

Ejemplares similares